ArticleRheumatology and therapy2022
Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers.
Article in Rheumatology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Article
- Treatment of Wounds That Are Difficult to Heal with Photobiomodulation: A Pilot Study.Healthcare (Basel, Switzerland) · 2025Article
- Selective bactericidal efficacy of 465-nm blue light phototherapy against standard and canine wound pathogens: AnVeterinary world · 2025Article
- Rapid, Safe, and Tolerable Healing of Pediatric Skin Injuries with Blue Light Therapy: An Observational Case Series.Children (Basel, Switzerland) · 2025Article
- Overcoming challenges of clinical cell therapies for Parkinson's disease with photobiomodulation.Interdisciplinary medicine · 2024Article
- Photobiomodulation at 660 nm Stimulates In Vitro Diabetic Wound Healing via the Ras/MAPK Pathway.Cells · 2023Article
- Photobiomodulation with Blue Light on Wound Healing: A Scoping Review.Life (Basel, Switzerland) · 2023Article
- Low-Dose Blue Light (420 nm) Reduces Metabolic Activity and Inhibits Proliferation of Human Dermal Fibroblasts.Life (Basel, Switzerland) · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSkin ulcers (SU) represent one of the most frequent manifestations of systemic sclerosis (SSc), occurring in almost 50% of scleroderma patients. SSc-SU are often particularly difficult to treat with conventional systemic and local therapies. In this study, a preliminary evaluation of the role and effectiveness of blue light photobiomodulation (PBM) therapy with EmoLED
methodsWe retrospectively analyzed 12 consecutive SSc patients with a total of 15 SU on finger hands. All patients were treated with adequate systemic therapy and local treatment for SU; after a standard skin ulcer bed preparation with debridement of all lesions, EmoLED
resultsThe application of EmoLED
conclusionsThe positive clinical results and the absence of side effects suggest that EmoLED
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.